Skip to main content

Table 3 Correlation between target gene protein levels and clinicopathological parameters of 99 BC cases

From: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivotumor growth

Variable EIF4A2 ANKRD46
  Low (n = 21) High (n = 78) P* Low (n = 47) High (n = 52) P*
Age (years)       
   < 48 8 39 0.332 23 24 0.782
   ≥ 48 13 39   24 28  
Pathologic grade       
   I 2 20 0.115 14 10 0.221
   II, III 19 58   33 42  
Clinical stage**       
   I, II 15 61 0.514 41 37 0.051
   III 6 17   6 15  
Lymph node status       
   Metastasis 14 43 0.342 23 34 0.098
   No Metastasis 7 35   24 18  
ER status       
Negative 12 36 0.371 18 32 0.021
Positive 9 42   29 20  
PR status       
Negative 11 28 0.170 11 29 0.001
Positive 10 50   36 23  
CerbB2 status       
0,1+ 17 41 0.019 29 18 0.832
2+,3+ 4 37   31 21  
  1. *Two-sided Pearson Chi-Square Test; ** there were no stage IV patients because all the cases selected were surgical patients without neoadjuvant therapy to avoid the effect of the preoperative radiotherapy and/or chemotherapy on miRNAs; EIF4A2, eukaryotic translation initiation factor 4A2 protein; ANKRD46, ankyrin repeat domain 46 protein; ER, estrogen receptor; PR, progesterone receptor; CerbB2, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.
\